Ajmaline

Summary

Ajmaline (CHEMBL5314404) is a phase-3 clinical-stage small molecule (ATC C01BA05); indicated across 1 condition.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: C01BA05
• Indications: 1 condition
• Clinical trials: 6
• Chemistry: 326.4 Da · C20H26N2O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL5314404
Name	Ajmaline
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	3000261
ATC	C01BA05
Molecular formula	C20H26N2O2
Molecular weight	326.4
InChIKey	CJDRUOGAGYHKKD-OVXZWHIBSA-N

SMILES: CC[C@H]1[C@@H]2C[C@H]3[C@H]4[C@@]5(C[C@@H]([C@@H]2[C@H]5O)N3[C@@H]1O)C6=CC=CC=C6N4C

IUPAC name: (1R,9R,10S,12R,13S,14R,16S,17R,18R)-13-ethyl-8-methyl-8,15-diazahexacyclo[14.2.1.01,9.02,7.010,15.012,17]nonadeca-2,4,6-triene-14,18-diol

Also known as: Ajmaline, NSC-15627, Rauwolfine, ajmaline, SID144204279, AJMALINE

Targets

Targets

Broader ChEMBL bioactivity targets: 5 (assay-derived). Sample: Voltage-gated L-type calcium channel, Sodium channel alpha subunit, Voltage-gated inwardly rectifying potassium channel KCNH2, Cytochrome P450 2D6, Voltage-dependent L-type calcium channel subunit alpha-1C.

Bioactivity

ChEMBL activities: 3 potent at pChembl ≥ 5 of 5 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
CYP2D6	6	IC50	1000	nM	CHEMBL_ACT_7634595
KCNH2	5.98	IC50	1040	nM	CHEMBL_ACT_15257948
SCN1A	5.09	IC50	8200	nM	CHEMBL_ACT_15257889

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication record carries no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 6.

Phase distribution

Phase	Trials
Not specified	4
PHASE4	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00702117	PHASE4	COMPLETED	Ajmaline Utilization in the Diagnosis and Treatment of Cardiac Arrhythmias
NCT02933437	PHASE2	UNKNOWN	The Response To Ajmaline Provocation in Healthy Subjects
NCT02641431	Not specified	COMPLETED	Epicardial Ablation in Brugada Syndrome
NCT03491475	Not specified	UNKNOWN	Echocardiography During Ajmaline Test
NCT03524079	Not specified	COMPLETED	Right Ventricle Morphology and Hemodynamics in BrS
NCT04580992	Not specified	UNKNOWN	Defining the Electrocardiographic Effect of Propofol on the Ajmaline Provocation Drug Challenge: A Prospective Trial

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).